Chu et al. have revealed that patients with pathologic features of high grade T1 disease harbored more TP53, ERBB2/Her2, and RB1 mutations and a genomic profile more similar to T2 tumors than NMIBC, suggesting an increased risk of infiltration and metastasis [25]; Meanwhile, NCCN guidelines show that chemotherapy given after TURBT may prevent tumor cell implantation and recurrence in select subgroups of patients [26]. Here, TP53 is linked to neoplasm.